LP0058-1005 - A Phase I, Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects When Administered as an Immediate and Modified Release Formulation

Trial Profile

LP0058-1005 - A Phase I, Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects When Administered as an Immediate and Modified Release Formulation

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2015

At a glance

  • Drugs LEO 32731 (Primary)
  • Indications Psoriasis
  • Focus Pharmacokinetics
  • Sponsors LEO Pharma
  • Most Recent Events

    • 10 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 21 Jan 2015 According to ClinicalTrial.gov record, planned End Date changed from 1 Jul 2014 to 1 Jan 2015.
    • 21 Jan 2015 According to ClinicalTrial.gov record, planned primary completion date changed from 1 Jul 2014 to 1 Jan 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top